Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006291 · ClinicalTrials.gov registry record · Phase 2
Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination
A Phase 2 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT00006291: Completed Phase 2 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00006291 is a Phase 2 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 100 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006291, a Phase 2 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to see if adding an HIV vaccine (ALVAC-HIV vCP1452), IL-2 (interleukin-2, a protein found in the blood that helps boost the immune system), or both to anti-HIV-drug therapy is safe, tolerable, and effective in controlling viral load (level of HIV in the body). (This study has been changed to clarify drug name.) Anti-HIV drugs can help reduce a patient's viral load. However, HIV can still remain in CD4 cells (cells of the immune system that help fight infection). Combining an HIV vaccine, IL-2, or both with anti-HIV drugs may help reduce the number of HIV-infected cells.
Conditions Studied
Interventions
- DRUG Aldesleukin
- BIOLOGICAL ALVAC(2)120(B,MN)GNP (vCP1452)
Study Locations (20)
California
- USC CRS - Los Angeles
- UCLA CARE Center CRS - Los Angeles
- Stanford CRS - Palo Alto
- Ucsf Aids Crs - San Francisco
- Santa Clara Valley Med. Ctr. - San Jose
- San Mateo County AIDS Program - San Mateo
- Marin County Dept. of Health & Human Services, HIV/AIDS Program & Specialty Clinic - San Rafael
- Harbor-UCLA Med. Ctr. CRS - Torrance
Indiana
- Indiana Univ. School of Medicine, Infectious Disease Research Clinic - Indianapolis
- Indiana Univ. School of Medicine, Wishard Memorial - Indianapolis
- Methodist Hosp. of Indiana - Indianapolis
New York
- Beth Israel Med. Ctr., ACTU - New York
- NY Univ. HIV/AIDS CRS - New York
Alabama
- Alabama Therapeutics CRS - Birmingham
Colorado
- University of Colorado Hospital CRS - Aurora
Florida
- Univ. of Miami AIDS CRS - Miami
Georgia
- The Ponce de Leon Ctr. CRS - Atlanta
Hawaii
- Univ. of Hawaii at Manoa, Leahi Hosp. - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Est. Completion | 2005-10 |
| Phase | Phase 2 |
What the finished NCT00006291 record still lists
NCT00006291 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (78% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Aldesleukin is the first listed.
NCT00006291 names 20 study sites across 10 states, led by California, Indiana, New York.
Frequently Asked Questions
What is clinical trial NCT00006291 about?
NCT00006291 is a clinical study titled "Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination". The purpose of this study is to see if adding an HIV vaccine (ALVAC-HIV vCP1452), IL-2 (interleukin-2, a protein found in the blood that helps boost the immune system), or both to anti-HIV-drug therapy is safe, tolerable, and effective in controlling viral load (level of HIV in the body). (This stud...
What is the current status of trial NCT00006291?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. Estimated completion is 2005-10.
What conditions does trial NCT00006291 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00006291?
The interventions under investigation include: Aldesleukin (DRUG), ALVAC(2)120(B,MN)GNP (vCP1452) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00006291?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006291 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00006291's enrollment target sits among peer trials
100 267th of 542 higher than 267 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning